This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AllScripts Healthcare (MDRX) Tops Q1 Earnings Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 26.67% and -0.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AllScripts Healthcare (MDRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts' (MDRX) Solution Gets Selected by Revo Health
by Zacks Equity Research
Allscripts' (MDRX) Practice Management solution to improve financial and operational performance of all i-Health clinics of Revo Health.
Allscripts' (MDRX) Sunrise Platform Picked by Mercy Iowa City
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform gets selected by Mercy Iowa City, thereby enabling the former to help in delivering better patient outcomes and accelerating the future of healthcare.
AllScripts (MDRX) Down 2.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock, courtesy of solid prospects.
Allscripts (MDRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allscripts (MRDX) witnessed expansion in gross margin, driven by better-than-expected software revenues and consistent decline in operating expenses.
AllScripts Healthcare (MDRX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 31.82% and 1.86%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect weak segmental performance.
Can AllScripts (MDRX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
AllScripts (MDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Information industry. OMCL, NXGN and NH are well positioned to gain.
Allscripts (MDRX) Extends Tie-Up With US Orthopedic Alliance
by Zacks Equity Research
Allscripts (MDRX) extends strategic partnership with US Orthopedic Alliance to form a more scalable orhopedic services technology platform.
3 Biggest MedTech Trends to Watch in 2021 for Better Returns
by Sriparna Ghosal
Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.
3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021
by Sriparna Ghosal
Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.
Allscripts (MDRX) Completes Sale of CarePort Health Business
by Zacks Equity Research
Allscripts' (MDRX) agreement with WellSky empowers providers with efficient care transitions and better patient health outcomes.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock on the back of its solid prospects.
3 Telemedicine Stocks to Gain in 2021 on Digital Health Boom
by Debanjana Dey
Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.
Allscripts' (MDRX) Veradigm Collaborates With HealthVerity
by Zacks Equity Research
Allscripts (MDRX) and HealthVerity will be committed toward catering to specific industry needs by helping clients design linked data solutions that are fit-for-purpose.
Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat
by Zacks Equity Research
Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.
AllScripts Healthcare (MDRX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 11.11% and -4.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AllScripts Healthcare (MDRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AllScripts (MDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts Completes Sale of EPSi Business to Strata
by Zacks Equity Research
Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.
3 Sectors Areas to Invest in Ahead of Q3 Earnings
by Urmimala Biswas
Here is a rundown of how sectors like digital health, consumer staple and e-learning have performed in the third quarter of 2020.
MDRX vs. HMSY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDRX vs. HMSY: Which Stock Is the Better Value Option?